Exelixis (EXEL) Gains from Investment Securities (2014 - 2015)
Exelixis (EXEL) posted quarterly Gains from Investment Securities of $730000.0 for Q2 2019, up 249.28% quarter-over-quarter from $209000.0 in Q1 2018.
Analysis
Exelixis (EXEL) Gains from Investment Securities (2014 - 2015) Analysis & Trends
Exelixis' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $730000.0 for Q2 2019.
- In Q2 2019, Gains from Investment Securities changed N/A year-over-year to $730000.0; the TTM figure through Sep 2019 stood at $730000.0 (up 249.28% YoY), while the FY2018 annual figure was $209000.0, down 92.99% from the prior year.
- Gains from Investment Securities for Q2 2019 stood at $730000.0, up from $209000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $2.5 million in Q3 2016, with the low at $209000.0 in Q1 2018.
- The 5-year median for Gains from Investment Securities is $730000.0 (2019), against an average of $1.3 million.
- The sharpest annual moves came in 2015 and 2017: Gains from Investment Securities jumped 131.57% in 2015, then dropped 6.13% in 2017.
- Exelixis' Gains from Investment Securities stood at $549000.0 in 2015, then jumped by 254.28% to $1.9 million in 2016, then advanced by 20.36% to $2.3 million in 2017, then plunged by 91.07% to $209000.0 in 2018, then soared by 249.28% to $730000.0 in 2019.
- Business Quant data shows EXEL's Gains from Investment Securities at $730000.0 in Q2 2019, $209000.0 in Q1 2018, and $2.3 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2015 | 549,000.00 |
| Dec 31, 2014 | 76,000.00 |
| Sep 30, 2014 | -62,000.00 |
| Jun 30, 2014 | -115,000.00 |
| Mar 31, 2014 | -1.74 Mn |